Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 p.m. ET in New York.
加利福尼亞州卡爾斯巴德，2024年9月10日（GLOBE NEWSWIRE）——開發嚴重退行性遺傳病治療方法的生物技術公司Design Therapeutics, Inc.（納斯達克股票代碼：DSGN）今天宣佈，管理層將參加美國東部時間2024年9月19日星期四中午12點45分在紐約舉行的2024年坎託全球醫療保健會議的爐邊談話。
A live webcast of the fireside chat will be available here and in the investors section of the company's website at . The webcast will be archived for at least 30 days following the presentation.
爐邊聊天的網絡直播將在這裏和公司網站的投資者欄目中播出。網絡直播將在演示結束後存檔至少 30 天。
About Design Therapeutics
Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC gene targeted chimera small molecules. The company's GeneTAC molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington's disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
關於設計療法
Design Therapeutics是一家生物技術公司，基於其GeneTac基因靶向奇美拉小分子平台開發一類新療法。該公司的Genetac分子旨在調高或降低特定致病基因的表達，以解決疾病的根本原因。除了爲弗裏德賴希共濟失調患者開發的主要GeneTac小分子Dt-216外，該公司還在推進福克斯角膜內皮營養不良症、亨廷頓氏病和1型肌強直性營養不良症的項目。多種基因組藥物的發現工作正在進行中。欲了解更多信息，請訪問 designtx.com。
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
聯繫人：
蕾妮·萊克
THRUST 戰略
renee@thrustsc.com
譯文內容由第三人軟體翻譯。